Seres Therapeutics(MCRB)
Focus: Seres Therapeutics is a public biotech company developing microbiome-derived therapeutics to treat infectious diseases and antibiotic-associated complications. The company is a pioneer in the live biotherapeutic drug space with a clinical-stage pipeline focused on C. difficile infection and inflammatory bowel disease.
Profile data last refreshed 32m ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
5+5 this month
Growing — net +5 jobs in 30d
5 jobs added vs 0 removed. Steady team buildout.
Should You Work at Seres Therapeutics?
AI assessmentA high-risk, high-reward opportunity for scientists and clinicians betting on microbiome therapeutics innovation, but severely constrained by cash position and lack of immediate hiring visibility.
Why Work Here
- Pioneer in emerging microbiome therapeutic space with differentiated science and unmet clinical needs in infectious diseases
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$0K
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT02437500Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
N/AHelp build intelligence for Seres Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.